PAN MERSEY AREA PRESCRIBING COMMITTEE MEETING

Minutes of the Meeting held on Wednesday 25 March 2015 in The Gallery Room, at The Venue, Civic Way, off Poplar Bank, Huyton L36 9GD

Present:

	MEMBERS	Present	Apologies
Dr M G Semple (Chair)	Senior Lecturer in Child Health – Alder Hey Children's NHS Foundation Trust	Х	
Isam Badhawi (Paul	Senior Pharmacist – Liverpool Women's NHS		Х
Skipper attending)	Foundation Trust		
Catrin Barker	Chief Pharmacist – Alder Hey Children's NHS Foundation Trust	Х	
Dr Rob Barnett	LMC Representative, Liverpool		Х
Nicola Baxter	Head of Medicines Optimisation – West Lancs CCG	Х	
Alison Butt (Maureen Hendry attending)	Joint Head of Medicines Management - Liverpool Community Health		Х
Neil Chilton	Deputy Chief Pharmacist, 5 Boroughs Partnership, Mental Health Trust		Х
Dr Catherine Doyle	Clinical Lead Medicines Management – Warrington CCG		Х
Dr Janice Eldridge	GP Medicines Management Lead – Southport & Formby CCG	Х	
Alison Ewing (Paul Skipper attending)	Clinical Director Pharmacy – The Royal Liverpool & Broadgreen University Hospitals NHS Trust		Х
Dr Anna Ferguson	GP Clinical Lead – South Sefton CCG	Х	
Dr Claire Forde	CCG Governing Body Member, Prescribing Lead – Halton CCG	Х	
Simon Gelder (Mike Welsby attending)	Chief Pharmacist – St Helens & Knowsley Teaching Hospitals NHS Trust		Х
Margaret Geoghegan	Head of Medicines Management – St Helens CCG	Х	
Donna Gillespie- Greene	Deputy Head of Meds Management – North West Commissioning Support Unit	Х	
Gillian Gow	Chief Pharmacist – Liverpool Heart & Chest Hospital NHS Foundation Trust		Х
Paul Gunson	Interim Senior Pharmacist, Knowsley CCG (representing Mark Pilling)	Х	
Dr Dan Hawcutt	Alder Hey Children's NHS FT	Х	
Maureen Hendry	Practice pharmacist/Interface support pharmacist, Liverpool Community Health (representing Alison Butt)	X	
Dr Aftab Hossain	Clinical Lead, Prescribing – Knowsley CCG		Х
Peter Johnstone	Prescribing Commissioner – Liverpool CCG	Х	
Dr Tom Kennedy	Consultant at RLBUHT and Chair of D&T		Х
Dr Tom Kinloch	LMC Representative , Mid-Mersey LMC		Х
Lee Knowles	Chief Pharmacist – Mersey Care NHS Trust		Х
Jenny Lunn	Pharmaceutical Adviser & Team Lead, Medicines Management – Warrington CCG	Х	
Susanne Lynch	CCG Lead Medicines Management – South Sefton CCG and Southport & Formby CCG	Х	
Dr Lisa Manning	LPC Representative		Х
Diane Matthew	Chief Pharmacist, Warrington & Halton Hospitals NHS Foundation Trust	Х	

Jen Matthewman	Bridgewater Community Trust (representing Heather Tomlinson)	Х	
Dr Sid McNulty	Consultant Endocrinologist/Chair Drug & Therapeutics Committee – St Helens & Knowsley Teaching Hospitals NHS Trust	Х	
Dr Neil Mercer	Consultant Anaesthetist/Chair Drug & Therapeutics Committee – Aintree University Hospitals NHS Trust	Х	
Mark Pilling (Paul Gunson attending)	Interim Head of Medicines Management – Knowsley CCG		Х
Lucy Reid	Lead Pharmacist – Halton CCG Locality Medicines Management Team	Х	
Dr Shamim Rose	GP Prescribing Lead & Board Sponsor – Liverpool CCG		Х
Steve Simpson	Deputy Chief Pharmacist – Southport and Ormskirk NHS Trust	Х	
Paul Skipper	Deputy Director of Pharmacy – The Royal Liverpool & Broadgreen University Hospitals NHS Trust (representing Alison Ewing)	Х	
Dave Thornton	Principal Pharmacist, Clinical Services – Aintree University Hospitals NHS Trust (representing Mags Norval)	Х	
Heather Tomlinson (Jen Matthewman attending)	Senior Clinical Pharmacist – Bridgewater Community Healthcare NHS Trust		Х
Mike Welsby	St Helens & Knowsley Teaching Hospitals NHS Trust (representing Simon Gelder)	Х	
Dr Julie Whittaker	St Helens CCG Governing Body Medicines Management Lead GP		Х
IN ATTENDANCE			
Erika Baker	Senior Pharmacist – North West CSU		Х
Anne Henshaw	Senior Pharmacist – North West CSU	Х	
Susan Maire	Medicines Management Team, LCH	Х	
Graham Reader	Senior Pharmacist – North West CSU	Х	
Helen Stubbs	Senior Pharmacist – North West CSU	Х	
Jan Ward	Prescribing Adviser North West CSU	Х	

	APC/15/19 – Welcome and Apologies for Absence	Action:
1	The Chair welcomed the members and introduced new member Dr Dan Hawcutt of Alder Hey.	
	The Chair then accepted the apologies of the following: Dr Bisarya (West Lancs CCG), Dr Catherine Doyle, Alison Ewing (Paul Skipper attending), Alison Butt (Maureen Hendry attending), Simon Gelder (Mike Welsby attending), Dr Tom	
	Kennedy, Dr Lisa Manning, Heather Tomlinson (Jen Matthewman attending), Mark Pilling (Paul Gunson attending), Dr Julie Whittaker, Dr Rob Barnett, Jenny Jones and Erika Baker.	
	APC/15/20 – Declarations of Interest and Quoracy Check	
2	A quoracy check confirmed that this meeting was not quorate. All members confirmed that they were happy to continue with the meeting unless there were any contentious topics.	
	There were no declarations of interest at this meeting.	
3	APC/15/21 – Minutes of the previous meeting and matters arising.	
	15/21/01 – Minutes from the Previous Meeting The Minutes were agreed to be an accurate record of the previous meeting.	

	15/21/02 – Matters Arising	
	APC Policy The APC Policy has been amended to include a small section relating to behaviour – see page 10 of APC Policy document. Donna Gillespie-Greene has also included a paragraph about guests at the meeting, to the effect that if members want to bring guests then they must inform APC Chair and/or Professional Secretary prior to the meeting and, if approved, the guests can then be advised about their speaking/voting rights.	
	A member drew attention to page 15 and the reference to a PPI Sub-group. Currently there is no PPI Sub-group so the meeting confirmed that this is to be removed.	DGG
	Chair of APC – expressions of interest Two expressions of interest in the post of Chair have been received. The Chair asked if any further expressions of interest could be made to DGG by close of play today. After that, DGG will circulate the names of interested parties by means of a 'voting email' and ask members for their anonymous vote.	ALL/ DGG
	Pharmacist Ordering Prescription Guidelines As the mid-Mersey website will be closing down, it was confirmed that the existing guidelines previously hosted on the Mid-mersey site will be transferred to the Pan Mersey website, so members can continue to refer to these.	
4	APC/15/22 – New Medicines 15/22/01 – Infliximab biosimilars The patent for Infliximab expired at the end of February 2015 and two biosimilar infliximab products became available in March 2015. NMSG felt that to undertake an evidence review would add little (as there are few published clinical trials available) and it was felt that this was likely to be a procurement issue – a view which was also agreed at the CCG Leads and Chief Pharmacists' meeting on 11 March 2015.	
	AH asked members if they are in agreement with allowing the issue to be dealt with via the procurement route and not taking this through the NMSG process. There were no objections. The formulary will be updated to include all the relevant national information.	
	The APC members were then asked whether the same priniciple should apply to any future biosimilars or if they should be considered on a case by case basis. One member suggested that it should be on a case by case basis as it is too soon to make a blanket decision for all biosimilars. The committee agreed with this stance.	
	15/22/02 – Aclidinium & Formoterol This new combination inhaler is a combination of two existing products, already approved for use in the Pan Mersey formulary, so this would normally be passed to FGSG. However, as NMSG is looking at two other LAMA/LABA combination inhalers, AH proposed that a draft combined statement is produced by the NMSG to cover all three products. This was approved.	
	15/22/03 – Brimonidine gel This item is for information only. There has been a considerable delay in producing a statement and AH gave members an update. Feedback from dermatologists suggested that there may be a place for this where patients would otherwise be referred for laser therapy. The NMSG has been unable to clarify whether laser therapy can be accessed for facial erythema of rosacea and the cost-effectiveness of laser v Brimonodine gel. It is anticipated that a recommendation will be submitted to the APC in April 2015.	
	15/22/04 – Grey Statement Summary The NMSG will complete a full evidence review of Aflibercept in macular oedema secondary to branch retinal vein occlusion (BRVO) and aim to bring this back to the APC within six months.	
	15/22/05 – Infliximab, Adalimumab & Golimumab in UC The NICE TA 329 approving these 3 treatments came out at the end of February. The statement and the costing table was presented to the committee and a question was raised about whether the PAS (patient access scheme) can be mentioned. AH will check what the NICE wording is and make any amendments necessary. Based on this, the attendees confirmed their approval and there were no objections.	

1522/06 - Uncelidinium in COPD A summary of the green statement was presented to the APC. There were no questions and there were no objections. AH will speak to FGSG about including this treatment on to the COPD guidelines in response to a request from members. 5 APC/15/23 - Formulary and Guidelines 7 April 10 - Guidelines for Managing Malnutrition in Adults in the Community A guideline and appendices 1-4, based on the Liverpool guidance with amendments, has been produced to update the weising Mid Mersey Medicines Management Board guideline. Recommended products are listed alphabetically. Some feedback was received back from the consultation about training needed, but it was felt that this was a matter for implementation within organisations. There were no objections to the guideline, and it was agreed. 1522/02 - "Jaydess" statement Jaydess is similar to Mirena but it is designed to be in place for 3 years rather than 5 years. It is a little bit smaller so its may be easier to insert. Cost per year is similar. Stakeholder feedback was described, which had been incorporated into the statement. There were concerns about ecotopic pregnancy risk bud overall efficacy is on a par with other methods of contraception. A member asked about the position regarding public health commissioning but this is outide of the scope of the APC. The green statement was agreed. 1522/30 - "Magnaspartate" addition to formulary The GreSS proposed that Magnasparatelis is added to the formulary as an oral magnesium supplement as first cholice, as amber. The proposed entry gives details, including about the smalil groupus o patients who it may not be suitable for a			
 5 If 223/01 - Guidelines for Managing Malnutrition in Adults in the Community A guideline and appendices 1-4, based on the Liverpool guidance with amendments, has been produced to update the existing Mid Mersey Medicines Management Board guideline. Recommended products are listed alphabetically. Some feedback was received back from the consultation about training needed, but it was fet that this was a matter for implementation within organisations. There were no objections to the guideline, and it was agreed. <i>15/23/02 - "Jaydess" statement</i> Jaydess is similar to Mirena but it is designed to be in place for 3 years rather than 5 years. It is a little bit smaller so it may be easier to insert. Cost per year is similar. Stakeholder feedback was described, which had been incorporated into the statement. There were a cobjections to the guideline, and it was agreed. <i>15/23/02 - "Jaydess" statement</i> Jaydess is similar to Mirena but it is aptential risk with both products. The failure rate, compared to Mirena was also queried liceocy is on a par with other methods of contraception. A member asked about the position regarding public health commissioning but this is outside of the scope of the APC. The green statement was agreed. <i>15/23/03 - "Magnaspartate" addition to formulary</i> The FGSG proposed that Magnaspartate is added to the formulary as an oral magnesium supplement as first choice, as amber. The proves dentry gives details, including about the small groups of patients who it may not be suitable for and for whorm magnesium glycorphopsphate unlicensed special may still be required (e.g. patients with diabetes or fluid restriction). This was agreed. <i>15/23/04 - Baclofen alcohol abstinence addition to formulary</i> an alternative to acamprosate and is currently established		A summary of the green statement was presented to the APC. There were no questions and there were no objections. AH will speak to FGSG about including this treatment on to the	
Jaydess is similar to Mirena but it is designed to be in place for 3 years rather than 5 years. It is a little bit smaller so it may be easier to insert. Cost per year is similar. Stakeholder feedback was described, which had been incorporated into the statement. There were concerns about ectopic pregnancy risk being greater than with Mirena but there is limited evidence to support this, and it is a potential risk with both products. The failure rate, compared to Mirena was also queried, but overall efficacy is on a par with other methods of contraception. A member asked about the position regarding public health commissioning but this is outside of the scope of the APC. The rGSG proposed that Magnaspartate is added to the formulary as an oral magnesium supplement as first choice, as amber. The proposed entry gives details, including about the small groups of patients who it may not be suitable for and for whom magnesium glycerophopsphate unlicensed special may still be required (e.g. patients with diabetes or fluid restriction). This work arose as a result of queries from GP practices so FGSG looked at this. It is used as an alternative to acamprosate and is currently established practice. Members agreed. 15/23/04 - Bactoten alcohol abstinence addition to formulary This work arose as a result of queries from GP practices so FGSG looked at this. It is used as an alternative to acamprosate and is currently established practice. Members agreed to the addition of Bactofen (for alcohol abstinence) to the formulary as amber, except in Southport & Formby and South Sefton where it will be red due to differences in commissioned alcohol services. 15/23/05 - NetFormulary report Chapters 1-4 and 7-13 are on the website in Ne	5	15/23/01 – Guidelines for Managing Malnutrition in Adults in the Community A guideline and appendices 1-4, based on the Liverpool guidance with amendments, has been produced to update the existing Mid Mersey Medicines Management Board guideline. Recommended products are listed alphabetically. Some feedback was received back from the consultation about training needed, but it was felt that this was a matter for implementation within organisations.	
The FGSG proposed that Magnaspartate is added to the formulary as an oral magnesium supplement as first choice, as amber. The proposed entry gives details, including about the small groups of patients who it may not be suitable for and for whom magnesium glycerophopsphate unlicensed special may still be required (e.g. patients with diabetes or fluid restriction). This was agreed. 15/23/04 - Baclofen alcohol abstinence addition to formulary This work arose as a result of queries from GP practices so FGSG looked at this. It is used as an alternative to acamprosate and is currently established practice. Members agreed to the addition of Baclofen (for alcohol abstinence) to the formulary as amber, except in Southport & Formby and South Sefton where it will be red due to differences in commissioned alcohol services. 15/23/05 - NetFormulary report Chapters 1-4 and 7-13 are on the website in NetFormulary format (and Chapter 6 is in progress). The next two stages are:- 1. Paediatrics: Chapters are currently being reviewed with Alder Hey Hospital to include paediatrics - Chapters 2 and 10 are done, Chapter 9 is in process and either Chapter 3 or 4 will be reviewed next. 2. Consistency: Now the formulary is on the NetFormulary the next stage is to refine the presentation. App - IOS and Android Apps are available for viewing the Pan Mersey formulary on NetFormulary via mobile devices. A brief guide to using the App will be forwarded to members. Attendees were asked to actively promote the App as they see fit within their organisations. 6 APC/1524 - Safety 1524/01 - Safety Interface Update 7 There has been a Safety Interface r		Jaydess is similar to Mirena but it is designed to be in place for 3 years rather than 5 years. It is a little bit smaller so it may be easier to insert. Cost per year is similar. Stakeholder feedback was described, which had been incorporated into the statement. There were concerns about ectopic pregnancy risk being greater than with Mirena but there is limited evidence to support this, and it is a potential risk with both products. The failure rate, compared to Mirena was also queried, but overall efficacy is on a par with other methods of contraception. A member asked about the position regarding public health commissioning but this is outside of the scope of the APC.	
This work arose as a result of queries from GP practices so FGSG looked at this. It is used as an alternative to acamprosate and is currently established practice. Members agreed to the addition of Baclofen (for alcohol abstinence) to the formulary as amber, except in Southport & Formby and South Sefton where it will be red due to differences in commissioned alcohol services. 15/23/05 - NetFormulary report Chapters 1-4 and 7-13 are on the website in NetFormulary format (and Chapter 6 is in progress). The next two stages are:-1. Paediatrics: Chapters are currently being reviewed with Alder Hey Hospital to include paediatrics - Chapters 2 and 10 are done, Chapter 9 is in process and either Chapter 3 or 4 will be reviewed next.2. Consistency: Now the formulary is on the NetFormulary the next stage is to refine the presentation.App - IOS and Android Apps are available for viewing the Pan Mersey formulary on NetFormulary via mobile devices. A brief guide to using the App will be forwarded to members. Attendees were asked to actively promote the App as they see fit within their organisations.6 APC/15/24 - Safety 15/24/01 - Safety Interface Update There has been a Safety interface reporting system on the website for a while so EB has done some work with Kieron Donlon to redesign and simplify the form and it is now available on the website.		The FGSG proposed that Magnaspartate is added to the formulary as an oral magnesium supplement as first choice, as amber. The proposed entry gives details, including about the small groups of patients who it may not be suitable for and for whom magnesium glycerophopsphate unlicensed special may still be required (e.g. patients with diabetes or fluid restriction).	
6 APC/15/24 - Safety 6 APC/15/24 - Safety Interface Update The rest Comparison		This work arose as a result of queries from GP practices so FGSG looked at this. It is used as an alternative to acamprosate and is currently established practice. Members agreed to the addition of Baclofen (for alcohol abstinence) to the formulary as amber, except in Southport & Formby and South Sefton where it will be red due to differences in	
paediatrics - Chapters 2 and 10 are done, Chapter 9 is in process and either Chapter 3 or 4 will be reviewed next. 2. Consistency: Now the formulary is on the NetFormulary the next stage is to refine the presentation. App – IOS and Android Apps are available for viewing the Pan Mersey formulary on NetFormulary via mobile devices. A brief guide to using the App will be forwarded to members. Attendees were asked to actively promote the App as they see fit within their organisations. <i>GR/ALL</i> 6 APC/15/24 - Safety Interface Update There has been a Safety interface reporting system on the website for a while so EB has done some work with Kieron Donlon to redesign and simplify the form and it is now available on the website.		Chapters 1-4 and 7-13 are on the website in NetFormulary format (and Chapter 6 is in	
presentation. App – IOS and Android Apps are available for viewing the Pan Mersey formulary on NetFormulary via mobile devices. A brief guide to using the App will be forwarded to members. Attendees were asked to actively promote the App as they see fit within their organisations. GR/ALL 6 APC/15/24 – Safety 15/24/01 – Safety Interface Update There has been a Safety interface reporting system on the website for a while so EB has done some work with Kieron Donlon to redesign and simplify the form and it is now available on the website. GR/ALL		paediatrics - Chapters 2 and 10 are done, Chapter 9 is in process and either Chapter 3	
NetFormulary via mobile devices. A brief guide to using the App will be forwarded to members. Attendees were asked to actively promote the App as they see fit within their organisations. ALL 6 APC/15/24 - Safety 15/24/01 - Safety Interface Update There has been a Safety interface reporting system on the website for a while so EB has done some work with Kieron Donlon to redesign and simplify the form and it is now available on the website.			
6 15/24/01 – Safety Interface Update There has been a Safety interface reporting system on the website for a while so EB has done some work with Kieron Donlon to redesign and simplify the form and it is now available on the website.		NetFormulary via mobile devices. A brief guide to using the App will be forwarded to members.	
When the user puts the information into the form it automatically uploads itself on to the	6	15/24/01 – Safety Interface Update There has been a Safety interface reporting system on the website for a while so EB has done some work with Kieron Donlon to redesign and simplify the form and it is now available on the	
		When the user puts the information into the form it automatically uploads itself on to the	

	database. Both primary and secondary care use it to report anything at all to do with the prescribing system (but not the drugs).	
	The Chair asked if this is something that could be put on hospital websites and suggested that it is a question to take back to members' D & T committees.	
7	APC/15/25 – Any Other Business	
'	15/25/01 – AOB	
	APC Chair The Chair reminded members to forward any expressions of interest for the role of APC Chair to DGG by close of play today.	ALL
	New Venue DGG reported that following her visit to V7 (a possible new venue for APC meetings) she has established that it is only available for 3 to 4 out of the next 10 meetings. Members were asked if they want meetings to be split between V7 and The Venue Huyton or do they prefer to remain at The Venue. Some members expressed the opinion that if there is no charge for using V7 then this route should be followed to save money.	
8	APC/15/26Date, Time and Venue of the next meetingThe next APC meeting will be on Wednesday 29 April 2015 at 1.30 – 3.30pm. Venue: TBC	

The agenda and minutes of this meeting may be made available to public and persons outside of The Pan Mersey Area Prescribing Committee Health Community in order to comply with requests made under the Freedom of Information Act 2000.